Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

IMPORTANCE: Tumor mutational burden (TMB), as measured by whole-exome sequencing (WES) or a cancer gene panel (CGP), is associated with immunotherapy responses. However, whether TMB estimated by circulating tumor DNA in blood (bTMB) is associated with clinical outcomes of immunotherapy remains to be...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:JAMA Oncol
Hoofdauteurs: Wang, Zhijie, Duan, Jianchun, Cai, Shangli, Han, Miao, Dong, Hua, Zhao, Jun, Zhu, Bo, Wang, Shuhang, Zhuo, Minglei, Sun, Jianguo, Wang, Qiming, Bai, Hua, Han, Jiefei, Tian, Yanhua, Lu, Jing, Xu, Tongfu, Zhao, Xiaochen, Wang, Guoqiang, Cao, Xinkai, Li, Fugen, Wang, Dalei, Chen, Yuejun, Bai, Yuezong, Zhao, Jing, Zhao, Zhengyi, Zhang, Yuzi, Xiong, Lei, He, Jie, Gao, Shugeng, Wang, Jie
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Medical Association 2019
Onderwerpen:
Original Investigation
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512308/
https://ncbi.nlm.nih.gov/pubmed/30816954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.7098
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items